行情

CYCC

CYCC

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

0.5950
+0.0655
+12.37%
盘后: 0.6190 +0.024 +4.03% 19:23 12/06 EST
开盘
0.5450
昨收
0.5295
最高
0.5972
最低
0.5370
成交量
23.01万
成交额
--
52周最高
1.180
52周最低
0.2813
市值
1,023.40万
市盈率(TTM)
-1.1318
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CYCC 新闻

  • Edited Transcript of CYCC earnings conference call or presentation 13-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.3天前
  • 报告:秘鲁2019年三季度倒闭公司数量同比增五成
  • 中国新闻网.3天前
  • 英国保守党支持率较工党的领先优势扩大至12个百分点
  • 新浪财经综合.3天前
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.3天前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

CYCC 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

Webull提供Cyclacel Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。